LegoChem Bio’s Phase II clinical trial of ‘Super Antibody’ designated for accelerated approval by FDA

Published: 2018-02-14 16:27:00
Updated: 2018-02-14 10:58:24

LegoChem Biosciences(LegoChem Bio) officially announced that Delpazloid(LCB01-0371), a Phase II clinical trial pipeline, was designated as a medicine for the Fast Track process by the U.S. Food and Drug Administration(FDA).

Delpazolid, an antibody developed by LegoChem Bio on its own, has been o...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.